Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet (12 SQ-HDM) in children with allergic rhinitis/rhinoconjunctivitis with or without asthma (MT-12): a randomised, double-blind, placebo-controlled, phase III trialResearch in context

• Main Authors: Antje Schuster (Author), Davide Caimmi (Author), Hendrik Nolte (Author), Silviya Novakova (Author), Jan Mikler (Author), Majken Hougaard Foss-Skiftesvik (Author), Anne Sofie Østerdal (Author), Andrzej Emeryk (Author), Remi Gagnon (Author), Oliver Pfaar (Author)
• Format: Book
• Published: Elsevier, 2025-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: Allergic rhinitis/rhinoconjunctivitis (AR/C) induced by house dust mites (HDM) often begins in childhood and negatively impacts a child's quality of life. The daily burden can be further compounded by comorbid asthma. Allergen immunotherapy is the only available treatment t...